Zymtech.no

Prospects of utilization of the Enzymatic Protein Hydrolysate
AMIZATE® in complex therapy of patients with HIV-infection
and AIDS.
By Gennady A. Ermolin, Professor (Immunology), Doctor of Science (Cardiology, Immunology)
HIV-infection is the sluggishly progressing pathological process caused by long presence in an organism of the human immunodeficiency virus (HIV), described by infringement of the function of the immune system, resulting in doom of the patient. Acquired immunodeficiency syndrome (AIDS) – a serious stage of the HIV-infection – with the expressed deterioration of the immune system resulting in development of serious forms of infectious diseases and/or malignant neoplasm which do not occur in individuals with normal immunity. In the course of the illness of patients with AIDS the following serious symptoms are frequently observed: Anorexia, infringement of swallowing, fever, diarrhea, weight loss; Chronic inflammatory diseases of the intestine accompanied with dysbacteriosis; Renal failure at which deficiency of essential amino acids is induced; Liver failure, at which deficiency of branched chain amino acids (leucine, isoleucine, valine) is induced, and leading to enlargement of the liver encephalopathy; Chronic pancreatitis which is accompanied by reduced digestion of food which again results in sharp deficiency in the organism of the essential (indispensable) amino acids and short peptides (e.g. hormones and neurotransmitters); Dystrophy of the myocardium (myocardiopathy) owing to deficiency of essential Patients with untreated AIDS have short life expectancy, and their death is not caused by the HIV infection itself, but from other infections and oncological diseases which arise and progress due to an eroded immune system. These diseases render serious and frequently irreversible pathological influence on all organs and physiological systems of AIDS patients. HIV acts as a trigger of serious clinical symptomatology of AIDS, but does not produce it on its own. With such extensive pathology as in patients with AIDS the metabolism of all substances in the organism is broken. In AIDS patients, as a result, a disastrous increase in the acute deficiency of all essential amino acids and short peptides will inevitably occur. Treatment of AIDS patients is normally done with a combination of: pathogenetic therapy (to fight viruses, bacteria, fungi and parasites); symptomatic therapy (to address symptoms due to deterioration of normal functioning of organs and tissues of the organism).
Furthermore, a side effect of anti-retrovirus drugs (which have to be taken for life) can be a
very serious deterioration of the function of the gastrointestinal tract, liver, kidneys, and
pancreatic gland. In patients with AIDS it is necessary to restrain the increasing number of
deficiencies by constantly administering diets with various additives.
In therapy of patients with AIDS various types of synthetic admixtures are stipulated to
satisfy the proteinaceous energy demands of the organism. However, in practice such
admixtures are rarely used, mainly because of their high cost.
New prospects for the maintenance of quality of life of patients with HIV-infection and AIDS
are opened by the biologically active food additive – AMIZATE – manufactured by the
company ZYMTECH PRODUCTION AS of Norway. This product is a hydrolysate of proteins
from saltwater fish. The hydrolysis of the proteins is carried out in close to physiological
conditions with the help of enzymes excreted from the organs of the fish itself. The product is
refined with the help of advanced biological techniques.
A unique feature of the AMIZATE is that the product contains the full range of indispensable
(essential) as well as dispensable (non-essential) amino acids in the natural balanced
concentrations characteristic of animal tissues. Furthermore, the AMIZATE contains a
complete range of short peptides, minerals, trace elements, and vitamins of group B. Such a
product would be technically difficult to compose from synthetic components, and would be
prohibitively expensive.
Zymtech Production’s AMIZATE, as biologically active food supplement, can be applied in a
complex symptomatic therapy of patients with AIDS. In such therapy AMIZATE could
become a uniquely effective nutritional supplement.
References:

1. Bozzette S. A., Sattler F. R., Chiu J. et al. A controlled trial of early adjunctive treatment
with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency
syndrome. N. Engl. J. Med. 323:1451—1457, 1990.
2. Brody S., Mitsuya H., Yarchoan R., Pavlakis G. N. Antiretroviral therapy in AIDS. Ann.
Intern. Med. 113:604—618, 1990.
3. Clark S. J., Saag M. S., Decker W. D. et al. High titers of cytopathic virus in plasma of
patients with symptomatic primary HIV-I infection. N. Engl. J. Med. 324:954—960, 1991.
4. Concorde Coordinating Committee. Concorde: MRC/ANRS randomized double-blind
controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet
343:871—881, 1994.
5. Coombs R. W., Collier A. C., Allain J. P. et al. Plasma viremia in human immunodeficiency virus infection. N. Engl. J. Med. 321:1626—1631, 1989. 6. Drugs for AIDS and associated infections. Medical Letter Drugs Ther. 35:79—86, 1993. 7. Glatt A. E., Chirgwin K. C., Landesman S. H. Treatment of infections associated with human immunodeficiency virus. N. Engl. J. Med. 318:1439—1448, 1988. 8. Jacobson M. A., Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann. Intern. Med. 108:585—594, 1988. 9. Johnston M. I., Hoth D. F. Present status and future prospects for HIV therapies. Science 260:1286—1293, 1993. 10. Larsen R. A., Leal M. A. E., Chan L. S. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann. Intern. Med. 113:183—187, 1990. 11. Lifson A. R., Rutherford G. W., Jaffe H. W. The natural history of HIV infection. J. Infect. Dis. 263:1497—1501, 1988. 12. Luft B. J., Remington J. S.: Toxoplasmic encephalitis. J. Infect. Dis. 157:1—6, 1988. 13. Masur H. K., Ognibene F. P., Yarchoan R. et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann. Intern. Med. 111:223—231, 1989. 14. Northfelt D. W., Kahn J. O., Volberding P. A. Treatment of AIDS-related Kaposi's sarcoma. Hematol. Oncol. Clin. North Am. 5:297—310, 1991. 15. Soave R., Johnson W. E. Cryptosporidium and Isospora belli infections. J. Infect. Dis. 157:225—229, 1988. 16. Sommadossi J. P. Nucleoside analogs: Similarities and differences. Clin. Infect. Dis. 16:57—115, 1993. 17. Weiss R. How does HIV cause AIDS? Science 260:1273—1278, 1993.

Source: http://www.zymtech.no/nyhetsbilder/9-zymtech%20aids%20memo%20by%20dr%20gennady%20ermolin%20may%202007.pdf